All In Biotech

Drug Trial Radar · NCT00942331

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

506

Actual

Start

Jul 15, 2009

Primary completion

Nov 2, 2018

Study completion Jun 15, 2021

Sponsor

Sponsor type
NIH
First posted
Jul 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bevacizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given with or without bevacizumab in treating patients with urinary tract cancer.

Conditions

  • Advanced Urothelial Carcinoma
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Prostate Carcinoma
  • Metastatic Renal Pelvis Urothelial Carcinoma
  • Metastatic Ureter Urothelial Carcinoma
  • Metastatic Urethral Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Stage IV Bladder Urothelial Carcinoma AJCC v7
  • Stage IV Prostate Cancer AJCC v7
  • Stage IV Renal Pelvis Cancer AJCC v7
  • Stage IV Ureter Cancer AJCC v7
  • Stage IV Urethral Cancer AJCC v7
  • Unresectable Urothelial Carcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • CisplatinDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Placebo AdministrationOther

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization to date of death due to any cause, assessed up to 7 years

Locations

873 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Hospital

    Mobile, Alabama

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • Community Cancer Institute

    Clovis, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Marin General Hospital

    Greenbrae, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Memorial Medical Center

    Modesto, California

  • El Camino Hospital

    Mountain View, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Northridge Hospital Medical Center

    Northridge, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Highland General Hospital

    Oakland, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Tumor Institute

    Oakland, California

  • Hematology and Oncology Associates-Oakland

    Oakland, California

  • Tom K Lee Inc

    Oakland, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Keck Medical Center of USC Pasadena

    Pasadena, California

  • Valley Care Health System - Pleasanton

    Pleasanton, California

Showing 40 of 873 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.